Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life
Wolfgang Schuette, Hans Tesch, Hartwig Büttner, Thomas Krause, Victoria Soldatenkova and Clemens Stoffregen*